OraSure Technologies Inc
OSUR2.410USD
+0.020+0.84%
Cierre 12/22, 16:00（ET）Cotizaciones retrasadas 15 min
174.16MCap. mercado
PérdidaP/E TTM
Más Datos de OraSure Technologies Inc Compañía
OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company improves the access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers. Its products and services include OraQuick ADVANCE Rapid HIV1/2 Antibody Test, OraQuick HIV Self-Test, and Diagnostics Direct Syphilis Health Check.
Información de OraSure Technologies Inc
Símbolo de cotizaciónOSUR
Nombre de la empresaOraSure Technologies Inc
Fecha de salida a bolsaNov 17, 1986
Director ejecutivoEglinton Manner (Carrie)
Número de empleados501
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 17
Dirección220 E First St
CiudadBETHLEHEM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal18015
Teléfono15036416115
Sitio Webhttps://www.orasure.com/
Símbolo de cotizaciónOSUR
Fecha de salida a bolsaNov 17, 1986
Director ejecutivoEglinton Manner (Carrie)
Ejecutivos de OraSure Technologies Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Kenneth J. (Ken) Mcgrath
Mr. Kenneth J. (Ken) Mcgrath
Chief Financial Officer
Chief Financial Officer
448.46K
-2.72%
Dr. Nancy J. Gagliano, M.D.
Dr. Nancy J. Gagliano, M.D.
Independent Director
Independent Director
160.25K
+1.33%
Mr. John P. Kenny
Mr. John P. Kenny
Independent Chairman of the Board
Independent Chairman of the Board
153.32K
+4.16%
Mr. Lelio Marmora
Mr. Lelio Marmora
Independent Director
Independent Director
130.76K
+93.09%
Hon Dr. David J. Shulkin, M.D.
Hon Dr. David J. Shulkin, M.D.
Independent Director
Independent Director
126.33K
+109.45%
Ms. Anne Messing
Ms. Anne Messing
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Robert W. Mcmahon
Mr. Robert W. Mcmahon
Independent Director
Independent Director
--
--
Mr. Jason Plagman
Mr. Jason Plagman
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Ms. Carrie Eglinton Manner
Ms. Carrie Eglinton Manner
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Steven K. (Steve) Boyd
Mr. Steven K. (Steve) Boyd
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Kenneth J. (Ken) Mcgrath
Mr. Kenneth J. (Ken) Mcgrath
Chief Financial Officer
Chief Financial Officer
448.46K
-2.72%
Dr. Nancy J. Gagliano, M.D.
Dr. Nancy J. Gagliano, M.D.
Independent Director
Independent Director
160.25K
+1.33%
Mr. John P. Kenny
Mr. John P. Kenny
Independent Chairman of the Board
Independent Chairman of the Board
153.32K
+4.16%
Mr. Lelio Marmora
Mr. Lelio Marmora
Independent Director
Independent Director
130.76K
+93.09%
Hon Dr. David J. Shulkin, M.D.
Hon Dr. David J. Shulkin, M.D.
Independent Director
Independent Director
126.33K
+109.45%
Ms. Anne Messing
Ms. Anne Messing
Chief Commercial Officer
Chief Commercial Officer
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Net product and services revenues - COVID-19
14.40M
46.09%
Net product and services revenues - HIV
9.86M
31.54%
Net product and service revenues -Molecular Products
4.13M
13.21%
Other revenues - Other non Product revenues
1.40M
4.47%
Net product and services revenues - Risk assessment testing
994.00K
3.18%
Otro
474.00K
1.52%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
19.85M
63.54%
Africa (Region)
8.03M
25.69%
Europe
2.12M
6.78%
Other Regions
1.25M
3.99%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Net product and services revenues - COVID-19
14.40M
46.09%
Net product and services revenues - HIV
9.86M
31.54%
Net product and service revenues -Molecular Products
4.13M
13.21%
Other revenues - Other non Product revenues
1.40M
4.47%
Net product and services revenues - Risk assessment testing
994.00K
3.18%
Otro
474.00K
1.52%
Estadísticas de accionistas
Actualizado: sáb., 15 de nov
Actualizado: sáb., 15 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
7.81%
Private Management Group, Inc.
7.55%
Neuberger Berman, LLC
5.86%
The Vanguard Group, Inc.
5.76%
Altai Capital Management, L.P.
5.21%
Otro
67.80%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
7.81%
Private Management Group, Inc.
7.55%
Neuberger Berman, LLC
5.86%
The Vanguard Group, Inc.
5.76%
Altai Capital Management, L.P.
5.21%
Otro
67.80%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
36.59%
Investment Advisor/Hedge Fund
27.60%
Hedge Fund
23.49%
Individual Investor
6.13%
Research Firm
2.26%
Pension Fund
0.47%
Bank and Trust
0.29%
Venture Capital
0.11%
Insurance Company
0.04%
Otro
3.02%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
451
66.91M
93.28%
-15.50M
2025Q2
473
72.08M
98.55%
-16.70M
2025Q1
483
70.23M
93.78%
-12.52M
2024Q4
475
70.81M
94.94%
-10.37M
2024Q3
471
70.30M
94.28%
-10.80M
2024Q2
477
73.05M
98.74%
-8.54M
2024Q1
473
74.45M
97.36%
-5.59M
2023Q4
464
73.29M
99.74%
-5.62M
2023Q3
456
72.50M
98.73%
-4.51M
2023Q2
452
70.73M
96.51%
-2.77M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
5.43M
7.43%
-141.00K
-2.53%
Jun 30, 2025
Private Management Group, Inc.
5.46M
7.47%
+1.04M
+23.64%
Jun 30, 2025
Neuberger Berman, LLC
4.16M
5.68%
-124.14K
-2.90%
Jun 30, 2025
The Vanguard Group, Inc.
4.17M
5.7%
-120.08K
-2.80%
Jun 30, 2025
Altai Capital Management, L.P.
3.75M
5.13%
+1.59M
+73.37%
Sep 02, 2025
Dimensional Fund Advisors, L.P.
3.84M
5.25%
+14.96K
+0.39%
Jun 30, 2025
Systematic Financial Management, L.P.
2.23M
3.05%
+581.93K
+35.33%
Jun 30, 2025
Renaissance Technologies LLC
2.28M
3.11%
-294.84K
-11.47%
Jun 30, 2025
Acadian Asset Management LLC
2.19M
3%
-563.24K
-20.44%
Jun 30, 2025
Millennium Management LLC
1.23M
1.69%
+28.80K
+2.39%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.44%
iShares US Small Cap Value Factor ETF
0.12%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.05%
iShares Micro-Cap ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
Avantis US Small Cap Equity ETF
0.02%
WisdomTree US SmallCap Fund
0.02%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
DFA Dimensional US Small Cap Value ETF
0.01%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.44%
iShares US Small Cap Value Factor ETF
Proporción0.12%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
Proporción0.05%
iShares Micro-Cap ETF
Proporción0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.04%
Avantis US Small Cap Equity ETF
Proporción0.02%
WisdomTree US SmallCap Fund
Proporción0.02%
ProShares UltraPro Russell2000
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
DFA Dimensional US Small Cap Value ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de OraSure Technologies Inc?
Los cinco principales accionistas de OraSure Technologies Inc son:
BlackRock Institutional Trust Company, N.A. posee 5.43M acciones, lo que representa el 7.43% del total de acciones.
Private Management Group, Inc. posee 5.46M acciones, lo que representa el 7.47% del total de acciones.
Neuberger Berman, LLC posee 4.16M acciones, lo que representa el 5.68% del total de acciones.
The Vanguard Group, Inc. posee 4.17M acciones, lo que representa el 5.70% del total de acciones.
Altai Capital Management, L.P. posee 3.75M acciones, lo que representa el 5.13% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 5.43M acciones, lo que representa el 7.43% del total de acciones.
Private Management Group, Inc. posee 5.46M acciones, lo que representa el 7.47% del total de acciones.
Neuberger Berman, LLC posee 4.16M acciones, lo que representa el 5.68% del total de acciones.
The Vanguard Group, Inc. posee 4.17M acciones, lo que representa el 5.70% del total de acciones.
Altai Capital Management, L.P. posee 3.75M acciones, lo que representa el 5.13% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de OraSure Technologies Inc?
Los tres principales tipos de accionista de OraSure Technologies Inc son:
BlackRock Institutional Trust Company, N.A.
Private Management Group, Inc.
Neuberger Berman, LLC
BlackRock Institutional Trust Company, N.A.
Private Management Group, Inc.
Neuberger Berman, LLC
¿Cuántas instituciones poseen acciones de OraSure Technologies Inc (OSUR)?
A fecha de 2025Q3, 451 instituciones poseen acciones de OraSure Technologies Inc, con un valor de mercado combinado de aproximadamente 66.91M, lo que representa el 93.28% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en -5.27%.
¿Cuál es la mayor fuente de ganancias de OraSure Technologies Inc?
El FY2025Q2, el segmento empresarial Net product and services revenues - COVID-19 generó la ganancia más alta para OraSure Technologies Inc, ascendiendo a 14.40M y representando el 46.09% de la ganancia total.
